GAR Capital’s Top Pick HIMS Gains 40% – More Upside Ahead?

Hims & Hers (HIMS), one of GAR Capital’s top stock picks of the year, just surged 40% following a major partnership with Novo Nordisk.

Hims & Hers Health HIMS , one of GAR Capital’s top 10 stock picks of the year , is making headlines with a significant surge in its stock price.

As of April 29, 2025, HIMS shares have soared over +40% YTD and for our portfolio, driven by a strategic partnership with pharmaceutical giant Novo Nordisk.

The Catalyst: Partnership with Novo Nordisk Hims & Hers has announced a collaboration with Novo Nordisk to offer the FDA-approved weight-loss drug Wegovy through its telehealth platform. Starting this week, U.S. customers can access Wegovy via Hims & Hers' website, bundled with a monthly membership costing $599. This move comes after the FDA removed semaglutide, Wegovy's active ingredient, from its drug shortage list, impacting Hims & Hers' previous sales of compounded versions .

The partnership aims to enhance access to obesity treatments, especially for cash-paying consumers, amid potential regulatory restrictions on compounded alternatives. Novo Nordisk has also partnered with other telehealth firms like Ro and LifeMD to expand Wegovy's availability.

GAR Capital's Strategic Insight GAR Capital identified HIMS as a top pick earlier this year, recognizing its potential in the evolving telehealth landscape. With this most recent development, our position in HIMS is now up over +40% , validating our strategic foresight.

Looking Ahead & Technical Target: This partnership doesn’t just expand Hims & Hers’ product reach — it firmly places them in the driver’s seat of the fast-growing weight-loss space. With momentum building and new partnerships in play, we still see plenty of upside ahead .

Even at current levels, we believe it’s still a solid entry.

🎯 Target 1: $50 (+42% from here)

🎯 Target 2: $60 (+70%)

🎯 Target 3: $70 — a full +100% move to retest all-time highs.

Stay sharp — and happy hunting.